ArticleArtificial organs2026
Plasma Adsorption Perfusion (BR-350) Versus Open Albumin Dialysis (OPAL) for Hyperbilirubinemia in Hepatic Failure in Cirrhotic Patients.
Article in Artificial organs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the last decades, various extracorporeal liver support systems were developed for hepatic failure with hyperbilirubinemia with the aim to clear the blood from protein-bound toxic molecules. Open albumin dialysis (OPAL) is a complex and expensive system that requires addition of human albumin. Plasma adsorption perfusion (PAP) using the anion exchange resin adsorber, BR-350, is an alternative liver support method that does not need additional blood products and is more cost-effective and less time-consuming.
methodsAt the University Hospital Essen, PAP using BR-350 was performed in a cohort of 9 patients with a mean of 6 sessions per patient. In a retrospective analysis, we compared the detoxification ability of PAP with that of the OPAL system conducted among 24 patients and with standard medical treatment (SMT) including hemodialysis that was performed among 24 patients. In addition, the technical effectiveness of a single session of PAP with BR-350 was compared with OPAL among 12 patients who were treated with both methods in a crossover design.
resultsThe first single session (30.7.3 ± 13.5 mg/dL to 25.8 ± 13.4 mg/dL, p = 0.02) and the complete therapy (30.7 ± 13.5 mg/dL to 16.2 ± 6.3 mg/dL, p = 0.004) with PAP using BR-350 resulted in a statistically significant decrease of bilirubin concentrations. The median relative reduction of bilirubin achieved at the end of liver support treatment was comparable between PAP and OPAL (47% vs. 40%, p = 0.29). PAP was associated with a higher bilirubin reduction than the SMT plus dialysis (47% vs. -30%, p = 0.0001). The crossover comparison between the single session of PAP using BR-350 and OPAL revealed similar mean relative reduction rates of bilirubin (11% vs. 10%, p = 0.81). The single session of OPAL was associated with a more pronounced decrease of alkaline phosphatase, gamma-glutamyltransferase, hemoglobin, platelets, and leucocytes compared to PAP.
conclusionsBoth studied methods had comparable efficacy in reducing bilirubin in our studied patients in contrast to the retrospective control group. Since other substrates may also be relevant in treating liver failure, more studies are required. Patients with concomitant renal failure benefit from OPAL, whereas PAP might be more eligible for patients with a high risk of bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.